Europe
TreeFrog Therapeutics, an expert stem cell company, announces that it has received close to €3M in non-dilutive funding from French and European programs.
Theragnostics announces a licence agreement with AstraZeneca for intellectual property (IP) that enables Theragnostics’ freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi Polymerase inhibitors) with an option to an exclusive licence for freedom to operate globally in the therapeutic field of certain selected radionuclide-labelled PARPi.
Royal DSM, a global science-based company active in Nutrition, Health and Sustainable Living celebrates 150 years of fermentation and biotechnology expertise and innovation at its site in Delft, the Netherlands.
Evonik Venture Capital has invested in a 3D-printing start-up in China that makes implants for neuro and spine surgery.
Acacia Pharma Group plc announces its unaudited interim results for the six-month period ended 30 June 2019.
Polyphor AG announced that the company will present at the 21st Annual H.C. Wainwright Global Investment Conference, taking place September 8-10, 2019 in New York City.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
Rentschler Biopharma SE announced its lineup of activities during the BioProcess International (BPI) Conference, being held September 9-12 in Boston, MA during Biotech Week Boston.
Orchard Therapeutics announced data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, a gene therapy for the treatment of mucopolysaccharidosis type I developed at the San Raffaele-Telethon Institute for Gene Therapy in Milan.
Orchard Therapeutics announced results from an integrated data analysis of OTL-200, a gene therapy in development for the treatment of metachromatic leukodystrophy (MLD) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.
PRESS RELEASES